Full-Time

VP Commercial

Site Solutions

Confirmed live in the last 24 hours

Veeva Systems

Veeva Systems

5,001-10,000 employees

Quality and regulatory software solutions provider

Compensation Overview

$180k - $300k/yr

+ Variable Bonus + Stock Bonus

Senior, Expert

Company Historically Provides H1B Sponsorship

Boston, MA, USA

Category
Strategic Account Management
Sales & Account Management
Required Skills
Product Management
Risk Management
Requirements
  • 7+ years of experience in business development, commercial, or sales leadership
  • 3+ years of experience working directly with clinical research sites, including executive leadership
  • Demonstrated track record of closed key accounts resulting in long-term, successful customers
  • Demonstrated experience working with Product teams to provide guidance on strengths & opportunities as a part of GTM strategy development
Responsibilities
  • Develop relationships with key leaders at research sites including AMCs, Community Healthcare, and Site Networks
  • Create a go-to-market strategy for an increasing innovative suite of products focused on site clinical research
  • Work across a collaborative team to define potential risks to the GTM strategy, and work with the General Manager to mitigate risks as appropriate
  • Execute on the GTM strategy to build key prospective accounts and guide them through the process to create long-standing relationships and successful customers

Veeva Systems offers software solutions for quality, regulatory, and advertising claims management, focusing on consumer products and chemical companies. Their cloud-based platform provides end-to-end visibility and traceability throughout the product journey, ensuring compliance with regulations and accelerating time-to-market. Unlike competitors, Veeva has expanded from the Life Sciences sector to address similar challenges in the Chemical and Consumer Goods markets. The company's goal is to modernize the product journey for clients while maintaining a subscription-based model for steady revenue.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Pleasanton, California

Founded

2007

Simplify Jobs

Simplify's Take

What believers are saying

  • Veeva's cloud solutions align with the rise of decentralized clinical trials.
  • The integration of AI-driven analytics enhances Veeva's data accuracy and speed.
  • Veeva's adaptable platforms support the expansion of personalized medicine.

What critics are saying

  • Emerging cloud-based software providers could erode Veeva's market share.
  • Rapid technological advancements may increase Veeva's R&D costs.
  • Data privacy concerns could impact Veeva's operations and client trust.

What makes Veeva Systems unique

  • Veeva specializes in cloud-based software for the life sciences industry.
  • Veeva's subscription model ensures continuous updates and improvements for clients.
  • Veeva offers end-to-end visibility and traceability in product journeys.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Parental leave

PTO

Free food

Health, dental, & vision insurance

Gym membership reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
PR Newswire
Mar 19th, 2025
Indero Marks 40Th Study Live With Veeva Rtsm

Specialized CRO standardizes on Veeva RTSM to drive operational efficiency and faster study timelinesBARCELONA, Spain, March 19, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Indero, formerly Innovaderm Research, successfully launched its 40th RTSM study on Veeva RTSM. By standardizing with Veeva RTSM, Indero has strengthened its clinical trial operations, harnessing advanced RTSM capabilities and expert support to drive efficiency, enhance process consistency, and streamline execution."As we continue to optimize our clinical trial operations, Veeva RTSM has driven more efficient processes and closer collaboration to ensure seamless execution," said Eric Hardy, senior director, biometrics at Indero. "Because of this added speed and effectiveness, we can help bring therapies to market faster, allowing our sponsors, sites, and patients to benefit sooner."The launch of Indero's 40th RTSM study highlights the continued collaboration between the two organizations. Since first adopting Veeva RTSM, Indero has worked closely with Veeva to continuously refine and implement standardized processes that drive long-term success for its clinical trials."With its enterprise standard RTSM approach, Indero is achieving greater long-term efficiency and reliability in their studies," said Steve Simmerman, general manager, Veeva RTSM. "Partnering with Indero to standardize clinical processes will further accelerate study timelines, demonstrating a streamlined approach that can advance the industry."Additional InformationTo learn more about Veeva's enterprise standard RTSM, visit www.veeva.com/rtsm.About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs

Simply Wall St
Mar 13th, 2025
Veeva Systems (NYSE:VEEV) Announces Tina Hunt's Retirement From Board Before 2025 Shareholders Meeting

Veeva Systems (NYSE:VEEV) announces Tina Hunt's retirement from board before 2025 shareholders meeting.

PR Newswire
Mar 11th, 2025
Boehringer Ingelheim Partners With Veeva To Launch 'One Medicine Platform'

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseasesINGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ -- Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the One Medicine collaboration in March 2022. The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases."Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world," said Oliver Fink, head of learning, process and digitalization at Boehringer Ingelheim. "Veeva Development Cloud provides the technology foundation for Boehringer's One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance.""By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals," said Rik van Mol, senior vice president, Veeva Development Cloud. "This is an exciting milestone toward realizing Veeva and Boehringer's shared mission to advance the use of data and technology to modernize clinical trials and deliver better patient outcomes."Veeva Development Cloud is the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.Additional InformationFor more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloudAbout Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health

PharmiWeb
Mar 11th, 2025
Boehringer Ingelheim Partners With Veeva To Launch ‘One Medicine Platform’

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseasesLondon, UK — 11 March 2025 — ​​​Today, ​Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud​.​​ They ​first announced the One Medicine collaboration in March 2022.​ ​The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development.With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimise trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.“Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world,” said Oliver Fink, head of learning, process and digitalisation at Boehringer Ingelheim. “Veeva Development Cloud provides the technology foundation for Boehringer’s One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance.”“By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals,” said Rik van Mol, senior vice president, Veeva Development Cloud. “This is an exciting milestone toward realising Veeva and Boehringer’s shared mission to advance the use of data and technology to modernise clinical trials and deliver better patient outcomes.”Veeva Development Cloud is the technology foundation for product development​,​ bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.Additional InformationFor more on Veeva Development Cloud, visit: veeva.com/DevelopmentCloudAbout Boehringer IngelheimBoehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain

Data Centre Magazine
Mar 11th, 2025
Boehringer Ingelheim Partners with Veeva to Launch 'One Medicine Platform'

INGELHEIM, Germany and BARCELONA, Spain, March 11, 2025 /PRNewswire/ - Today, Boehringer Ingelheim and Veeva Systems (NYSE: VEEV) have announced the launch of Boehringer's One Medicine Platform, powered by the successful implementation of Veeva Development Cloud.